A5024667998- Multiple Sclerosis Research Studies
- Polyomavirus and related diseases
- Autoimmune and Inflammatory Disorders Research
- Peripheral Neuropathies and Disorders
- Pregnancy and Medication Impact
- Reproductive System and Pregnancy
- Family Support in Illness
- Mycobacterium research and diagnosis
- Prion Diseases and Protein Misfolding
- Research on Leishmaniasis Studies
- Parkinson's Disease Mechanisms and Treatments
- Autoimmune Neurological Disorders and Treatments
- Immunodeficiency and Autoimmune Disorders
- Chronic Lymphocytic Leukemia Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Systems, Economic Evaluations, Quality of Life
- Systemic Sclerosis and Related Diseases
- Rheumatoid Arthritis Research and Therapies
- Long-Term Effects of COVID-19
- COVID-19 and Mental Health
- Parkinson's Disease and Spinal Disorders
- Human Mobility and Location-Based Analysis
- Full-Duplex Wireless Communications
- Gestational Trophoblastic Disease Studies
- Neurology and Historical Studies
Morriston Hospital
2013-2025
Swansea Bay University Health Board
2014-2024
National Health Service
2020
Neath Port Talbot Hospital
2020
Aneurin Bevan University Health Board
2015-2019
Cardiff University
2012-2017
Hywel Dda University Health Board
2017
University Hospital of Wales
2008-2017
Royal Victoria Infirmary
2017
University of Gothenburg
2017
<h3>Importance</h3> Within 2 decades of onset, 80% untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase irreversible disability accrual termed secondary progressive MS. The association between disease-modifying treatments (DMTs), and this conversion has rarely been studied never using validated definition. <h3>Objective</h3> To determine the use, type of, timing DMTs risk MS diagnosed <h3>Design, Setting, Participants</h3> Cohort study prospective data from...
Patients with multiple sclerosis (MS) may demonstrate better disease control when treatment is initiated on high-efficacy disease-modifying therapies (DMTs) from onset. This subgroup analysis assessed the long-term efficacy and safety profile of DMT ocrelizumab (OCR) as first-line therapy for early-stage relapsing MS (RMS). Post hoc exploratory analyses were performed in a treatment-naive patients RMS who received ≥1 dose OCR multicenter OPERA I/II (NCT01247324/NCT01412333) studies....
To describe a series of patients with relapsing multiple sclerosis (MS) who experienced significant and unexpected disease activity within the first 12 months after switching from fingolimod to alemtuzumab.Patients MS treated sequentially then alemtuzumab subsequent were identified by personal communication 6 different European neuroscience centers.Nine identified. Median duration treatment was 94 (39-215) follow-up time cycle 20 (14-21) months. Following infusion cycle, 8 at least 1...
Objective Older people with multiple sclerosis (MS) have a less active radiological and clinical presentation, but many still attain significant levels of disability; what drives worsening disability in this group? Methods We used data from the UK MS Register to characterize demographics features late‐onset (LOMS; symptom onset at ≥50 years), compared adult‐onset (AOMS; 18–49 years). performed pathology study separate cohort later (n = 18, mean age 54 years) versus AOMS 23, 29 Results In...
Introduction There remains a high unmet need for disease-modifying therapies that can impact disability progression in secondary progressive multiple sclerosis (SPMS). Following positive results of the phase 2 MS-STAT study, MS-STAT2 3 trial will evaluate efficacy and cost-effectiveness repurposed high-dose simvastatin slowing SPMS. Methods analysis be multicentre, randomised, placebo-controlled, double-blind participants aged between 25 65 (inclusive) who have SPMS with an Expanded...
The negative impact of smoking in multiple sclerosis is well established; however, there much less evidence as to whether cessation beneficial progression sclerosis. Adults with registered on the United Kingdom Multiple Sclerosis Register (2011-20) formed this retrospective and prospective cohort study. Primary outcomes were changes three patient-reported outcomes: normalized Physical Impact Scale (MSIS-29-Phys), Walking (MSWS-12) Hospital Anxiety Depression (HADS). Time event clinically...
Abstract Background Recent changes in the understanding and management of multiple sclerosis (MS) have increased role MRI supporting diagnosis disease monitoring. However, published guidelines on use MS do not translate easily into different clinical settings considerable variation practice remains. Here, informed by for MS, we identified a clinically informative protocol applicable variety settings, from district general hospitals to tertiary centres. Methods specialists geographically...
Background: People with MS (pwMS) have had higher rates of anxiety and depression than the general population before COVID-19 pandemic, placing them at risk experiencing poor psychological wellbeing during pandemic. Objective: To assess mental health its social/lifestyle determinants in pwMS first wave outbreak United Kingdom. Methods: This is a community-based, prospective longitudinal cohort cross-sectional case–control online questionnaire study. It includes 2010 from UK Register 380...
The fixed, progressive disability associated with late Multiple Sclerosis (MS) is known to have a major impact on patients and their families, but the of relapse earlier in disease course less well documented, particularly from patient׳s perspective. This study aimed understand effects for people MS (PwMS), focussing years immediately after starting modifying therapy (DMT) when experience may influence opinions its therapy.This was multi-centre, retrospective, observational research study,...
BackgroundThe proportion of people with relapsing-remitting multiple sclerosis prescribed disease modifying treatments (DMTs) in the United Kingdom (UK) is considered low compared other countries. There are differences DMT prescription rates between UK nations (England, Wales, Scotland, Northern Ireland). Despite this, there has been little research into decision-making processes and prescribing practices.ObjectiveTo investigate views experiences neurologists DMTs MS specialist nurses to...
Registries have the potential to tackle some of current limitations in determining long-term impact multiple sclerosis. Online assessments using patient-reported outcomes can streamline follow-up enabling large-scale, long-term, cost-effective, home-based, and patient-focused data collection. However, registry are sparsely sampled sensitivity relative clinician-reported scales is unknown, making it hard fully leverage their unique scope scale derive insights. This retrospective prospective...
Background Incorporating cognitive testing into routine clinical practice is a challenge in multiple sclerosis (MS), given the wide spectrum of both and physical impairments people can have time that requires. Shortened paper verbal assessments predominate but still are not used routinely. Computer-based tests becoming more widespread; however, changes how test implemented impact what exactly being assessed an individual. The Symbol Digit Modalities Test (SDMT) one validated forms part...
Anti-<i>N</i>-methyl-d-aspartate (NMDA) receptor encephalitis is a potentially reversible immune mediated disorder, often paraneoplastic and associated with antibodies to the NR1–NR2 subunit of NMDA receptor. Largely disorder young women, its diagnosis aided by characteristic clinical syndrome. In light this we describe 32-year-old female diagnosed multiple sclerosis (MS) who presented in 2009 after two separate episodes; left-sided optic neuritis right trigeminal nerve sensory disturbance....
Identification of multiple sclerosis (MS) cases in routine healthcare data repositories remains challenging. MS can have a protracted diagnostic process and is rarely identified as primary reason for admission to the hospital. Difficulties identification are compounded systems that do not include insurance or payer information concerning drug treatments non-notifiable disease.